🇺🇸 FDA
Patent

US 7368452

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

granted A61KA61K38/212A61K38/215

Quick answer

US patent 7368452 (Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon May 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue May 06 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K38/212, A61K38/215, A61P, A61P31/12